Atypical antipsychotics and the risk of extrapyramidal side effects;Atypische antipsychotica en de kans op extrapiramidale bijwerkingen

Tijdschrift voor Psychiatrie

Volumn 43, Issue 11, 2001, Pages 767-775

  Van Harten, P N ^a  

^a Symfora Groep   (Netherlands)

Author keywords

Acute dystonia; Akathisia; Atypical antipsychotics; Parkinsonism; Tardive dyskinesia

Indexed keywords

CLOZAPINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; EXTRAPYRAMIDAL SYMPTOM; MEDICAL INFORMATION; NONHUMAN; PARKINSON DISEASE; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TARDIVE DYSKINESIA;

EID: 0035165646     PISSN: 03037339     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. 50 years of controlled trials relevant to the care of people with schizophrenia
2. Multiple fixed doses of 'Seroquel' (quetiapine) in patients with acute exacerbation of schizophrenia: A comparison with haloperidol and placebo
3. Olanzapine versus placebo and haloperidol: Acute phase results of the North American double-blind olanzapine trial
4. Olanzapine versus haloperidol: Acute phase results of the international double-blind olanzapine trial
5. Randomised double-blind comparison of the incidence of tardive dyskinesia in patients with schizophrenia during long-term treatment with olanzapine or haloperidol
6. Extrapyramidal syndromes and new antipsychotic drugs: Findings in patients and non-human primate models
7. Olanzapine overdose cause of acute extrapyramidal symptoms
8. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients
9. The risk and benefits of clozapine versus chlorpromazine
10. Prevalence and severity of akathisia in patients on clozapine
11. A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder
12. A multicentre, double-blind, randomized comparison of quetiapine (ICI 204,636, 'Seroquel') and haloperidol in schizophrenia
13. Risperidone in the treatment of first-episode psychotic patients: A double-blind multicenter study
14. Clozapine replacement by quetiapine for the treatment of drug-induced psychosis in Parkinson's disease
15. Atypical antipsychotics in the treatment of drug-induced psychosis in Parkinson's disease
16. Atypical antipsychotics in the treatment of schizophrenia: Systematic overview and meta-regression analysis
17. 2 dopamine antagonists
18. Olanzapine aggravates parkinsonism: A randomized, double blind study in hallucinating Parkinson's disease patients
19. Severe akathisia during olanzapine treatment of acute schizophrenia
20. Lower incidence of tardive dyskinesia with risperidone compared with haloperidol in older patients
21. Clozapine for the treatment-resistant schizophrenic: A double-blind comparison with chlorpromazine
22. 2 receptor occupancy of olanzapine in schizophrenia: A PET investigation
23. 2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia
24. Relationship between dopamine D(2) occupancy, clinical response, and side effects: A double-blind PET study of first-episode schizophrenia
25. 2 receptor occupancy
26. 2 receptors with typical and atypical antipsychotics. A lack of extrapyramidal side-effects and new routes in schizophrenic research
27. The new atypical antipsychotics
28. Propranolol treatment of olanzapine-induced akathisia
29. 2 receptor occupancy by olanzapine or risperidone in young patients with schizophrenia
30. Dopaminereceptorbezetting door antipsychotica: Een overzicht van SPECT-en P E T-onderzoek
31. Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials
32. Pre-clinical pharmacology of atypical antipsychotic drugs: A selective review
33. Clinical management of clozapine patients in relation to efficacy and side-effects
34. A comparison of quetiapine and chlorpromazine in the treatment of schizophrenia
35. APA Practice Guideline for schizophrenia: Risperidone equivalents
36. Neurologic side effects in neuroleptic-naive patients treated with haloperidol or risperidone
37. Risperidone compared with new and reference antipsychotic drugs: In vitro and in vivo receptor binding
38. 2 receptors, yet occupy high levels of these receptors
39. Quetiapine in patients with schizophrenia. A high- and low-dose doubleblind comparison with placebo
40. Quetiapine for schizophrenia (Cochrane Review)
41. Tardive dyskinesia: A task force report of the American Psychiatric Association
42. Blind, controlled, long-term study of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapine or haloperidol
43. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders